CervoMed is trading 5.47% higher in pre-market at $1.53, compared with its November 5 close of $1.45; no direct catalyst has been identified. - No new company-specific announcement explaining the November 6 move surfaced in the search. - The latest identified company release was October 29, about published research on neflamapimod; it does not establish a direct catalyst for the pre-market gain.